PAPILLOMAVIRUS INFECTION. POSSIBILITIES FOR THE TREATMENT AND PREVENTION WITH INOSINE PRANOBEX


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper gives data on the prevalence of human papillomavirus (HPV) infection and describes current methods for the prevention, diagnosis, and screening of HPV-associated malignant diseases of the cervix uteri. It considers treatment options for papillomavirus infection and presents the experience with combination treatment using Isoprinosine. The results of performed international and the authors’ studies are shown.

Full Text

Restricted Access

About the authors

V. N PRILEPSKAYA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: v_prilepskaya@oparina4.ru
Moscow

E. P NOVIKOVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: taukita.matsuda@gmail.com
Moscow

L. A SULAMANIDZE

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: lika.sulamanidze@gmail.com
Moscow

G. M MZARELUA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: mzareluag@mail.ru
Moscow

References

  1. Стратегический документ «Подготовка к внедрению вакцины против ВПЧ в Европейском регионе». ВОЗ; 2008.
  2. Centers for Disease Control and Prevention. STD trends in the United States: 2010 national data for gonorrhea, chlamydia, and syphilis. http://www.cdc.gov/std/stats10/trends. htm. Accessed October 24, 2012.
  3. Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J., Vaccarella S. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366(9490): 991-8.
  4. Европейская ассоциация по патологии шейки матки и кольпоскопии, 2008 г.
  5. Woodman C.B., Collins S.I., Young L.S. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer. 2007; 7: 11-22.
  6. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol. Oncol. 2008; 110(3, Suppl. 2): S4-7.
  7. Snijders P.J., Steenbergen R.D., Heideman D.A., Meijer C.J. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J. Pathol. 2006; 208: 152-64.
  8. Einstein M.H., Schiller J.T., Viscidi R.P., Strickler H.D., Coursaget P., Tan T. et al. Clinician’s guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect. Dis. 2009; 9: 347-56.
  9. Lepique A.P., Rabachini T., Villa L.L. HPV vaccination: the beginning of the end of cervical cancer? A review. Mem. Inst. Oswaldo Cruz. 2009; 104: 1-10.
  10. Шварц Г.Я., Прилепская В.Н., Мынбаев О.А. Изопринозин в лечении папилломавирусной инфекции в гинекологической практике. М.; 2011. 83 с.
  11. Wheeler C.M. и соавт. J.Infect Dis.2007:194:1291-1299.
  12. Резолюция круглого стола российских специалистов. Разработка эффективных подходов к ведению пациентов с «минимальным» повреждением эпителия шейки матки и ВПЧ-инфекцией «XI-й Международный симпозиум по проблемам патологии нижнего отдела генитального тракта. Папилломавирусная инфекция: глобальная битва». Рим, 21 апреля 2012 г.
  13. Azar K.K., Tani M., Yasuda H., Sakai A., Inoue M., Sasagawa T. Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Hum. Pathol. 2004; 35: 1376-84.
  14. Goldie S.J., Kuhn L., Denny L., Pollack A., Wright T.C. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001; 285: 3107-15.
  15. Petry K.U., Menton S., Menton M., van Loenen-Frosch F., de Carvalho G.H., Holz B. et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br. J. Cancer. 2003; 88: 1570-7.
  16. Arbyn M., Simoens C., Van O.H., Foidart J.M., Goffin F., Simon P., Fabri V. Analysis of 13 million individual patient records pertaining to Pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996-2000). Prev. Med. 2009; 48(5): 438-43
  17. Dehn D., Torkko K.C., Shroyer K.R. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer. 2007; 111: 1-14.
  18. Костава М.Н., Прилепская В.Н. Возможности терапии папилломавирусной инфекции. Рус. Мед. Журн. 2009; 17 (1) 9-16.
  19. Линаск Л.Н., Григорьева Е.Е. Опыт применения изопринозина при заболеваниях шейки матки на фоне папилломавирусной инфекции у подростков и молодых женщин. Рус. Мед. Журн. 2008г;19:1221-5
  20. Кедрова А.Г., Леваков С.А., Челнокова Н.Н., Кожурина Е.В., Левакова С.Е., Саркисова А.А. Роль профилактических осмотров и первичного приема врача в женской консультации в выявлении субклинических и латентных форм папилломавирусной инфекции шейки матки и их мониторинг. Гинекология. 2011; 14 (1) 56-62.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies